Close Menu

NEW YORK (GenomeWeb) – Signal Genetics said in its Form 10-K today that its full-year 2014 revenue growth was flat year over year at $4.3 million. 

The molecular diagnostics firm also said that its net loss attributable to shareholders and company members was $7.9 million in 2014, compared to a net loss of $2.4 million in 2013. On a per-share basis, net loss retreated to $3.50 in 2014 compared to $12.23 in 2013. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.